Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 20,913 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Recruiting Phase 2 Interventional

Scalp Cooling in MBC

NCT04986579
View directory record Official record
Conditions
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Interventions
Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan
Device · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996
View directory record Official record
Conditions
Advanced Malignancies
Interventions
parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 30, 2026, 2:49 AM EDT
Withdrawn Phase 2 Interventional

rTMS for Treatment of Depressed Phase of Bipolar Disorder Type II

NCT00447096
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Mechanism of Change of Functional Analytic Psychotherapy

NCT03562962
View directory record Official record
Conditions
Interpersonal Functioning, Psychological Distress
Interventions
Functional Analytic Psychotherapy
Behavioral
Lead sponsor
University of Nevada, Reno
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

Red Blood Cell (RBC) Survival Following Transfusion in Infants

NCT00731588
View directory record Official record
Conditions
Neonatal Anemia
Interventions
Transfused Biotin RBCs - Adults Phase I, Transfused Biotin RBCs - Infants Phase II, Transfused Biotin RBCs - Infants Phase III
Biological
Lead sponsor
John A Widness
Other
Eligibility
1 Hour to 6 Months
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 30, 2026, 2:49 AM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Active, not recruiting Not applicable Interventional

A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy

NCT06414603
View directory record Official record
Conditions
Heart Transplant Failure and Rejection
Interventions
The Prospera™ Test
Diagnostic Test
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Terminated Phase 1 Interventional

A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

NCT04272203
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
Interventions
ABBV-184
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Fort Wayne, Indiana • Canton, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

Novel INXN-4001 Triple Effector Plasmid in Heart Failure

NCT03409627
View directory record Official record
Conditions
Heart Failure, Cardiovascular Diseases, Heart-Assist Device
Interventions
INXN-4001
Biological
Lead sponsor
Triple-Gene, LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Tucson, Arizona • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 30, 2026, 2:49 AM EDT
No Longer Available No phase listed Expanded access

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

NCT00162227
View directory record Official record
Conditions
HIV Infection
Interventions
Efavirenz
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 30, 2026, 2:49 AM EDT
Completed No phase listed Observational Results available

Adolescents' Well-being in Community-based Treatment Versus Residential Treatment

NCT06498427
View directory record Official record
Conditions
Adolescent Well-Being, Mental Disorders, Severe
Interventions
Not listed
Lead sponsor
Outcome Referrals, Inc.
Industry
Eligibility
12 Years to 18 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Framingham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

Memesto Wearable Device for Persons With Dementia

NCT05153161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memesto
Device
Lead sponsor
Edgewater Safety Systems, Inc.
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2024 · Synced Oct 30, 2026, 2:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

NCT07751042
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
STX-003, KEYTRUDA®
Biological
Lead sponsor
Strand Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)

NCT02491073
View directory record Official record
Conditions
Epilepsy
Interventions
blood draw
Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
7
States / cities
Sun City, Arizona • Boise, Idaho • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 30, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional Results available

Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00378573
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
docetaxel, gemcitabine, bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 26, 2010 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers

NCT02129569
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Psychoeducational intervention, behavioral intervention, counseling intervention, educational intervention, telephone-based intervention, questionnaire administration, quality-of-life assessment
Other · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 30, 2026, 2:49 AM EDT
Terminated Phase 2 Interventional Results available

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

NCT00290654
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen, Lumpectomy, brachytherapy
Drug · Procedure · Radiation
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Not applicable Interventional Results available

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

NCT04104022
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Prolonged Exposure Therapy, Attendance-based monetary incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Early Phase 1 Interventional

Novel Dose Escalation to Predict Treatment With Hydroxyurea

NCT02042222
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hydroxyurea
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 16 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Not applicable Interventional Results available

Examine the Feasibility and Acceptability of Project Support

NCT06391229
View directory record Official record
Conditions
Parent-Child Relations, Parenting, Child Mental Disorder
Interventions
Project Support
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Active, not recruiting No phase listed Observational

Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

NCT04431479
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Biospecimen Collection, Medical Chart Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Gainesville, Florida • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Not yet recruiting No phase listed Observational

Transcranial Doppler Evaluation After Endovascular Thrombectomy for Acute Ischemic Stroke (PRECISE-TCD)

NCT07013396
View directory record Official record
Conditions
Anterior Cerebral Artery Syndrome, Anterior Cerebral Artery Stroke, Acute Ischemic Stroke, Cardioembolic Stroke, Vasogenic Cerebral Edema
Interventions
Transcranial Doppler (TCD) examination
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

NCT00441896
View directory record Official record
Conditions
Infantile Spasms
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
4 Months to 24 Months
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 30, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

NCT03434262
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions
Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 39 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 30, 2026, 2:49 AM EDT